Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.84+0.01 (+1.41%)
Close on Nov 13, 2026Market cap $289.76MP/E –Yield 0.00%
Allogene Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Allogene Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $133.29M, down 19.9% year over year. For fiscal 2025 it was $150.15M, down 21.9% from the year before. The highest annual figure on record is $256.39M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.15M | -21.9% |
| FY2024 | Dec 31, 2024 | $192.30M | -20.8% |
| FY2023 | Dec 31, 2023 | $242.91M | -5.3% |
| FY2022 | Dec 31, 2022 | $256.39M | +16.4% |
| FY2021 | Dec 31, 2021 | $220.18M | +14.1% |
| FY2020 | Dec 31, 2020 | $192.99M | +33.5% |
| FY2019 | Dec 31, 2019 | $144.54M | -4.8% |
| FY2018 | Dec 31, 2018 | $151.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.93M | +34.6% |
| Q2 FY2026 | Jun 30, 2026 | $30.72M | -23.5% |
| Q1 FY2026 | Mar 31, 2026 | $32.00M | -36.2% |
| Q4 FY2025 | Dec 31, 2025 | $28.63M | -36.3% |
| Q3 FY2025 | Sep 30, 2025 | $31.16M | -30.3% |
| Q2 FY2025 | Jun 30, 2025 | $40.16M | -20.3% |
| Q1 FY2025 | Mar 31, 2025 | $50.20M | -3.9% |
| Q4 FY2024 | Dec 31, 2024 | $44.97M | -17.7% |
| Q3 FY2024 | Sep 30, 2024 | $44.71M | -2.7% |
| Q2 FY2024 | Jun 30, 2024 | $50.36M | -18.8% |
| Q1 FY2024 | Mar 31, 2024 | $52.26M | -34.9% |
| Q4 FY2023 | Dec 31, 2023 | $54.66M | -27.5% |
| Q3 FY2023 | Sep 30, 2023 | $45.98M | -27.8% |
| Q2 FY2023 | Jun 30, 2023 | $62.04M | +8.5% |
| Q1 FY2023 | Mar 31, 2023 | $80.24M | +33.4% |
| Q4 FY2022 | Dec 31, 2022 | $75.42M | +39.7% |
| Q3 FY2022 | Sep 30, 2022 | $63.64M | +8.4% |
| Q2 FY2022 | Jun 30, 2022 | $57.17M | +9.3% |
| Q1 FY2022 | Mar 31, 2022 | $60.16M | +9.0% |
| Q4 FY2021 | Dec 31, 2021 | $53.98M | +3.4% |
| Q3 FY2021 | Sep 30, 2021 | $58.72M | +14.2% |
| Q2 FY2021 | Jun 30, 2021 | $52.29M | +10.6% |
| Q1 FY2021 | Mar 31, 2021 | $55.18M | +31.3% |
| Q4 FY2020 | Dec 31, 2020 | $52.23M | +5.8% |
| Q3 FY2020 | Sep 30, 2020 | $51.42M | +28.6% |
| Q2 FY2020 | Jun 30, 2020 | $47.30M | +48.9% |
| Q1 FY2020 | Mar 31, 2020 | $42.04M | +79.6% |
| Q4 FY2019 | Dec 31, 2019 | $49.36M | +166.8% |
| Q3 FY2019 | Sep 30, 2019 | $40.00M | +267.9% |
| Q2 FY2019 | Jun 30, 2019 | $31.77M | -74.1% |
| Q1 FY2019 | Mar 31, 2019 | $23.40M | – |
| Q4 FY2018 | Dec 31, 2018 | $18.50M | – |
| Q3 FY2018 | Sep 30, 2018 | $10.87M | – |
| Q2 FY2018 | Jun 30, 2018 | $122.49M | – |
See a number that looks wrong?